US 12,144,875 B2
Compositions and methods for imaging
Lieping Chen, Beijing (CN); Liqun Luo, Beijing (CN); Zhenguo Wen, Beijing (CN); and Qianyong Liu, Beijing (CN)
Assigned to Tayu Huaxia Biotech Medical Group Co., Ltd., Beijing (CN)
Appl. No. 15/733,835
Filed by Tayu Huaxia Biotech Medical Group Co., Ltd., Beijing (CN)
PCT Filed May 31, 2019, PCT No. PCT/CN2019/089571
§ 371(c)(1), (2) Date Nov. 30, 2020,
PCT Pub. No. WO2019/228509, PCT Pub. Date Dec. 5, 2019.
Claims priority of application No. PCT/CN2018/089672 (WO), filed on Jun. 1, 2018.
Prior Publication US 2021/0213145 A1, Jul. 15, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 51/04 (2006.01); A61K 51/10 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC A61K 51/1027 (2013.01) [A61K 51/0497 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/33 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A method of determining the distribution of an immune checkpoint ligand in an individual, comprising:
(a) administering to the individual an imaging agent comprising an antibody moiety labeled with a radionuclide, wherein the antibody moiety specifically binds the immune checkpoint ligand, wherein the antibody moiety comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region (HC-CDR)1 comprising an amino acid sequence of SEQ ID NO: 41, a HC-CDR2 comprising an amino acid sequence of SEQ ID NO: 42, and a HC-CDR3 comprising an amino acid sequence of SEQ ID NO: 43; and a light chain variable region (VL) comprising a light chain complementarity determining region (LC-CDR)1 comprising an amino acid sequence of SEQ ID NO: 44, a LC-CDR2 comprising an amino acid sequence of SEQ ID NO: 45, and a LC-CDR3 comprising an amino acid sequence of SEQ ID NO: 46;
(b) imaging the imaging agent in the individual with a non-invasive imaging technique; and
(c) determining the expression level of the immune checkpoint ligand in a tissue of interest in the individual based on signals emitted by the imaging agent from the tissue.